Pitt B, Cohn J N, Francis G S, Kostis J B, Packer M, Pfeffer M A, Swedberg K, Yusuf S
University of Michigan Medical Center, Ann Arbor 48109-0366.
Clin Cardiol. 1992 May;15(5):323-9. doi: 10.1002/clc.4960150504.
Congestive heart failure (CHF) is a disorder characterized by a variety of clinical, biochemical, electrophysiological, and hemodynamic abnormalities. During the past two decades, numerous drugs have been employed in the treatment of this complex syndrome, and many agents have been shown to improve symptoms and ventricular function in patients with CHF. Because CHF is associated with a high risk of death, treatment should be directed not only toward the relief of symptoms, but also toward a reduction in mortality. Many variables have been shown to be related to survival; taken individually, however, each is limited in its utility in predicting prognosis. In recent years, large-scale studies with large sample sizes have directly assessed the effects of treatment on mortality in CHF. Results from these trials indicate that vasodilators and angiotensin-converting enzyme (ACE) inhibitors may improve mortality in patients with symptoms of heart failure. Additional trials are now in progress to evaluate the effect of treatment on patients with asymptomatic left ventricular dysfunction.
充血性心力衰竭(CHF)是一种以多种临床、生化、电生理和血流动力学异常为特征的病症。在过去二十年中,许多药物已被用于治疗这种复杂综合征,并且许多药物已被证明可改善CHF患者的症状和心室功能。由于CHF与高死亡风险相关,治疗不仅应针对症状缓解,还应旨在降低死亡率。许多变量已被证明与生存相关;然而,单独来看,每个变量在预测预后方面的效用都有限。近年来,大样本量的大规模研究直接评估了治疗对CHF死亡率的影响。这些试验的结果表明,血管扩张剂和血管紧张素转换酶(ACE)抑制剂可能改善有心力衰竭症状患者的死亡率。目前正在进行更多试验以评估治疗对无症状左心室功能不全患者的效果。